Although neutropenia and recurrent bacterial infections are frequent and are considered to be a main cause of morbidity and mortality in patients with T-LGL leukemia, this was not the case with our patient.
It is believed that sustained immune stimulation and a dysregulation of apoptosis underlies T-LGL leukemia pathogenesis, which is why immunosuppressive therapy remains the mainstay of treatment [4].
Few studies reported the use of purine analogs, polyche-motherapy, antithymocyte globulin and other regimens in refractory or relapsed T-LGL leukemia [1,2].